La vendita allo scoperto per Boston Scientific dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Boston Scientific. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Boston Scientific (NYSE:BSX) Azioni, Report sulle vendite allo scoperto

BOSTON SCIENTIFIC CORP

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Jim Cramer Reacts To Friday Market Plunge And Hints At His Next Buy

Mid Cap

Media

ANET

GRAL

RBRK

SHAK

TMDX

L&#39;esperto di Mad Money si esprime: quali titoli meritano attenzione e quali no? Analisi e consigli per gli investitori.

Jim Cramer: ecco le azioni che consiglia di comprare (e da evitare)

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BBIO

ISRG

ITCI

Anticipazioni di mercato rivelano titoli sanitari in crisi: azioni ad alto rischio da valutare per una potenziale vendita immediata.

Questi 4 titoli del settore sanitario potrebbero scoppiare: vendere subito?

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-watchman-access-system-issue-boston-scientific">https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-watchman-access-system-issue-boston-scientific</a>

Biotech

General

FDA Issues Early Alert On WATCHMAN Access System Issue From Boston Scientific

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-defibrillation-lead-issue-boston-scientific" title="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-defibrillation-lead-issue-boston-scientific">https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-defibrillation-lead-issue-boston-scientific</a>

FDA Provides Early Alert On Defibrillation Lead Issue From Boston Scientific; Certain ENDOTAK RELIANCE Defibrillation Leads With Expanded ePTFE Coated Coils May Impact Shock Efficacy And/or Require Early Replacement

Boston Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) short percent of float has risen 3.1% since its last report. The company recently reported that it has 19.57 million shares sold short, which is 1.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Boston Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753905636_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Boston Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Boston Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Boston Scientific's peer group average for short interest as a percentage of float is 4.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

What's Driving the Market Sentiment Around Boston Scientific?

Edwards Lifesciences&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.
The strong performance prompted the company to raise its full-year sales guidance, signaling renewed momentum in its core markets. The heart devices company reported sales of $1.53 billion on Thursday after hours, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.49 billion</a> and within the management guidance of $1.45 billion-$1.53 billion.
Sales grew 11.9% or 10.6% adjusted, with strength <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46616916/edwards-lifesciences-reports-second-quarter-results" rel="noreferrer noopener">across all product groups</a>. Edwards Lifesciences&nbsp;reported adjusted earnings of 67 cents, beating the consensus of 62 cents and the management guidance of <a target="_blank" href="https://www.benzinga.com/25/04/44992019/edwards-lifesciences-stock-earns-analyst-upgrade-as-growth-outlook-brightens" rel="noreferrer noopener">59-65 cents per share</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/legal/25/07/46528449/court-nixes-jury-award-over-medtronics-heart-valve-infringement-claim" rel="noreferrer noopener">Court Nixes Jury Award Over Medtronic&#8217;s Heart Valve Infringement Claim</a>
The company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1.1 billion, marking an increase of 8.9% (or 7.8% on a constant currency basis). The company said that TAVR growth for the quarter surpassed their expectations.
Transcatheter Mitral and Tricuspid Therapies (TMTT) segments achieved second-quarter sales of $134.5 million, demonstrating a year-over-year growth of 61.9%, or more than 57.1% on a constant currency basis.
In the Surgical segment, second-quarter global sales reached $267 million, an increase of 7.7% over the prior year, or 6.8% on a constant currency basis.
<h2 class="wp-block-heading">Outlook</h2>
&#8220;We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,&#8221; said Bernard Zovighian, CEO.
Edwards Lifesciences raised its 2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion compared to the consensus of $5.91 billion.
The company affirms fiscal 2025 adjusted earnings guidance of $2.40-$2.50 per share compared to the consensus of $2.48.
Edwards Lifesciences forecasts third-quarter adjusted earnings of 54-60 cents, compared to the consensus of 60 cents, and sales of&nbsp;$1.46 billion, $1.54 billion versus the consensus of $1.48 billion.
The company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion. Sales guidance for TMTT and Surgical product groups remains unchanged.
<h2 class="wp-block-heading">Analyst Insights: Goldman Sachs</h2>
Goldman Sachs said Friday that the second quarter of 2025 marked a key turning point for the company and reinforced its belief that Edwards is on track to achieve steady double-digit revenue growth again.
The firm noted that Edwards&#8217; core TAVR business is gaining momentum, even though the quarter only partially reflected the impact of the new asymptomatic indication and included just a small boost from Boston Scientific Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45655797/boston-scientific-scraps-this-aortic-valve-sticks-to-2025-outlook" rel="noreferrer noopener">planned market exit</a>. This gives Goldman confidence that the business will operate at a stronger baseline.
Analyst David Roman expects Edwards to get back to its previous strong performance over the next few years, with revenue growing over 10% and operating margins above 30%. With this kind of growth, Goldman Sachs believes the stock deserves a higher valuation, more than 30 times its earnings. The analyst maintains the Buy rating, raising the price <a target="_blank" href="https://www.benzinga.com/quote/EW/analyst-ratings" rel="noreferrer noopener">forecast from $89 to $101</a>.
<h2 class="wp-block-heading">Other Analysts</h2>
Several leading financial analysts re-evaluated their outlook on Edwards Lifesciences, with a general trend toward increased price forecasts.
Baird has maintained a Neutral rating on the company, slightly increasing its price forecast from $78 to $79. Deutsche Bank, on the other hand, reiterates a Buy rating and has significantly raised its price forecast from $85 to $94.
Evercore ISI affirms an In-Line rating, with a modest increase in its price forecast from $77 to $80. Wells Fargo continues to maintain an Overweight rating, raising its price forecast from $80 to $84.
Similarly, RBC Capital maintains an Outperform rating, lifting its price forecast from $85 to $89. Piper Sandler also keeps an Overweight rating, increasing its price target from $83 to $90.
Barclays maintains an Overweight rating and has raised its price forecast from $90 to $95. Finally, a Stifel analyst has reiterated a Buy rating, also increasing the price forecast from $90 to $95.
Price Action: EW stock is trading higher by 4.87% to $79.49 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46631878/mara-holdings-stock-slips-on-1-billion-note-offering-analyst-upgrade-offers-support" target="_blank" rel="noreferrer noopener">MARA Holdings Stock Slips On $1 Billion Note Offering, Analyst Upgrade Offers Support</a></li>
</ul>
Image via Shutterstock

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Price Target

Analyst Ratings

Movers

Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance

UBS analyst Danielle Antalffy maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $130 to $135.

UBS Maintains Buy on Boston Scientific, Raises Price Target to $135

Raymond James analyst Jayson Bedford maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Strong Buy and raises the price target from $121 to $124.

Raymond James Maintains Strong Buy on Boston Scientific, Raises Price Target to $124

Oppenheimer analyst Steven Lichtman maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Perform and raises the price target from $110 to $118.

Oppenheimer Maintains Perform on Boston Scientific, Raises Price Target to $118

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $118 to $124.

Wells Fargo Maintains Overweight on Boston Scientific, Raises Price Target to $124

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $120 to $125.

Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $125

In the preceding three months, 6 analysts have released ratings for Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $123.17, with a high estimate of $133.00 and a low estimate of $115.00. This current average has increased by 3.33% from the previous average price target of $119.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1753362098_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Boston Scientific among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$118.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Boston Scientific's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Boston Scientific's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>Unveiling the Story Behind Boston Scientific</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Boston Scientific: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Boston Scientific displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 20.93%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Boston Scientific's net margin is impressive, surpassing industry averages. With a net margin of 14.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Boston Scientific's ROE stands out, surpassing industry averages. With an impressive ROE of 3.06%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Boston Scientific's ROA excels beyond industry benchmarks, reaching 1.69%. This signifies efficient management of assets and strong financial health.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Boston Scientific Stock

Baird analyst David Rescott maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $117 to $123.

Baird Maintains Outperform on Boston Scientific, Raises Price Target to $123

Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $125 to $133.

Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $133

A wave of U.S. trade deals with key allies over the past 24 hours reignited Wall Street's rally and boosted investor risk <a href="https://www.benzinga.com/markets">appetite across global markets.</a>
President Donald Trump announced agreements with the Philippines, Indonesia and—most significantly—Japan, while the <a href="https://www.ft.com/content/460b7784-88d7-4324-9e4d-dc9692d15e72">Financial Times</a> reported that a U.S.-EU trade deal is imminent, expected to mirror the Tokyo framework.
The U.S.-Japan pact raises the baseline tariff on Japanese goods to 15% from 10%, sidestepping the previously threatened 25% level. Tariffs on Japanese autos have been cut from 25% to 15%. In return, Japan committed to investing $550 billion in the U.S. and easing access to American agricultural and industrial goods.
Markets cheered the progress. The S&amp;P 500 rose 0.5% to a new record high of 6,350, while the Dow Jones Industrial Average surged nearly 1%, or 450 points, nearing its own record. Small-cap stocks led the charge, with the Russell 2000 also jumping 1.0% to its highest level since February.
International equities soared even more. The iShares MSCI Japan Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWJ#NYSE">EWJ</a>) rallied 4.9% to an all-time high, the SPDR DJ Euro STOXX 50 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEZ#NYSE">FEZ</a>) climbed nearly 2%, and the iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) gained 2.1%.
As optimism over global trade thawed investor caution, demand for safe-haven assets dropped. Gold slid 1.4% to $3,383 per ounce, while silver dipped 0.3%. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 2% to $117,760. 
Next up: a major earnings test. Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) and IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) are all set to report results after Wednesday's close.
<h2 class="wp-block-heading">Wednesday&#8217;s Performance Of US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% Chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,272.31</td>
<td>1.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,892.90</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,340.17</td>
<td>0.5%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,077.71</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.5% to $580.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.9% to $448.95.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;held steady at $561.44.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1.1% to $225.66.</li>
<li>The&nbsp;Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) outperformed, up 1.8%; the&nbsp;Utilities&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.8%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stocks Movers</h3>
<ul class="wp-block-list">
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) soared 13% after beating the Street&#8217;s estimates last quarter.</li>
</ul>
Other stocks reacting to earnings reports included:
<ul class="wp-block-list">
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) down 3.54%</li>
<li>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) down 11.80%</li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) up 3.94%</li>
<li>NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) down 6.62%</li>
<li>Amphenol Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) up 3.15%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) up 1.32%</li>
<li>Moody's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) up 2.14%</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) up 2.30%</li>
<li>General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) up 6.47%</li>
<li>Fiserv Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FI#NASDAQ">FI</a>) down 16.10%</li>
<li>Infosys Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) up 1.66%</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) down 1.84%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) down 2.04%</li>
<li>TE Connectivity plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) up 10.30%</li>
<li>CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) up 6.34%</li>
<li>Otis Worldwide Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) down 10.32%</li>
<li>Teledyne Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) down 3.76%</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) up 8.84%</li>
<li>Northern Trust Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) down 3.53%</li>
<li>Rogers Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) up 0.29%</li>
<li>East West Bancorp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) down 2.16%</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) up 0.90%</li>
<li>Hasbro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) down 0.73%</li>
<li>Lamb Weston Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) up 16.08%</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46557704/trump-america-first-agenda-ai-industrial-stocks-defense-sector">Trump&#8217;s Sledgehammer Policies Have Ignited Wall Street&#8217;s Hottest Trade—And It&#8217;s Not AI </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Government

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Emerging Market ETFs

Commodities

Economics

Tech

ETFs

$BTC

COOP

CSGP

SPDR Dow Jones Industrial Average ETF Trust

EWBC

GOOGL

INFY

NTRS

OTIS

TSLA

Stocks Jump On Trump's Trade Deal Deluge Ahead Of Big Tech Earnings: What's Moving Markets Wednesday?

WIIM

Boston Scientific shares are trading higher after the company reported better-than-expected Q2 EPS and sales and raised its FY2025 EPS and sales guidance above consensus estimates.

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) momentum—and hint at where its next product <a href="https://www.benzinga.com/pressreleases/25/04/n44944464/boston-scientific-announces-results-for-first-quarter-2025">wins may come.</a>
Boston Scientific on Wednesday reported second-quarter 2025 revenues of $5.06 billion, beating the consensus estimate of $4.89 billion.
&#8220;This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth,&#8221; said Mike Mahoney, chairman and CEO, Boston Scientific.
The medical technology giant reported adjusted earnings of 75&nbsp;cents, beating the consensus of 72 cents and the management guidance of 71-73 cents.
Sales increased 22.8% on a reported basis, compared to the company's guidance range of 17.5%-19.5%, and 21.6% on an operational basis, 17.4% on an organic basis, compared to the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44952308/boston-scientific-raises-annual-outlook-after-strong-heart-devices-sales-in-q1-announces-cfo-transition" rel="noreferrer noopener">guidance range of 13%-15%</a>.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/05/45655797/boston-scientific-scraps-this-aortic-valve-sticks-to-2025-outlook" target="_blank" rel="noreferrer noopener">Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook</a>
The company's cardiovascular segment generated sales of $3.35 billion, rising 26.8% (25.5% operationally and 23.2% organically).
Boston Scientific reported a 29.3% growth in cardiology products to $2.65 billion and 18.3% in peripheral interventions, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46567180/boston-scientific-announces-results-for-second-quarter-2025" rel="noreferrer noopener">with sales of $698 million</a>.
MedSurg segment revenues increased to $1.72 billion, a 15.7% rise (14.7% operationally and 1% organically).
Urology led the way with a 28.9% increase in sales of $676 million. Neuromodulation sales increased 7.2% to $303 million, and Endoscopy sales increased 9.1% to $737 million.
Outlook: Boston Scientific forecasts net sales growth of approximately 18%-19% in 2025 on a reported basis and around 14%-15% on an organic basis, compared to prior guidance of 15%-17% and 12%-14%, respectively.
The company raised its adjusted earnings guidance from&nbsp;$2.87-$2.94&nbsp;to&nbsp;$2.95-$2.99, compared to the consensus of&nbsp;$2.92.
Boston Scientific expects third-quarter 2025 adjusted earnings of 70 cents to 72 cents versus the consensus of 70 cents.
The company estimates net sales growth for the third quarter of 2025, compared to the prior year period, to be approximately 17%-19% on a reported basis and 12%-14% on an organic basis.
Earlier in July, the U.S. Food and Drug Administration approved an expansion of the instructions for use labeling for Boston Scientific&#8217;s FARAPULSE Pulsed Field Ablation System.
The updated labeling now includes approval for the system in the treatment of drug-refractory, symptomatic persistent atrial fibrillation, an arrhythmia in which the heart beats abnormally for at <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46270661/boston-scientific-receives-fda-approval-for-expanded-labeling-of-farapulse-pulsed-field-ablation-s" rel="noreferrer noopener">least seven days</a>.
BSX Price Action: Boston Scientific shares were up 2.78% at $106.03 on Wednesday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/travel/25/07/46566803/delta-faces-lawmaker-backlash-over-ai-powered-ticket-pricing-senators-warn-it-could-exploit-travelers-with-personalized-fare-hikes" target="_blank" rel="noreferrer noopener">Delta Faces Lawmaker Backlash Over AI-Powered Ticket Pricing — Senators Warn It Could Exploit Travelers With Personalized Fare Hikes</a></li>
</ul>
Photo: Shutterstock

Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance

Global

During Conf Call, Boston Scientific Exec Says Anticipate Full-Year Tariff Headwind Of About $100M, Down From Previous Estimate Of About $200M

The company estimates net sales growth for the third quarter of 2025, versus the prior year period, to be in a range of approximately 17 to 19 percent on a reported basis, and 12 to 14 percent on an organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.44 to $0.46 and estimates adjusted EPS, excluding certain charges (credits), of $0.70 to $0.72.

Boston Scientific Sees Q3 2025 Adj EPS $0.70-$0.72 vs $0.70 Est; Sees Sales $4.920B-$5.010B vs $4.859B Est

Guidance for Full Year 2025
The company estimates net sales growth for the full year 2025, versus the prior year period, to be approximately 18 to 19 percent on a reported basis and 14 to 15 percent on an organic basis.&nbsp;
Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.89 to $1.93 and estimates adjusted EPS, excluding certain charges (credits), of $2.95 to $2.99.

Boston Scientific Raises FY2025 Adj EPS Guidance from $2.87-$2.94 to $2.95-$2.99 vs $2.92 Est; Raises FY2025 Sales Guidance from $19.259B-$19.594B to $19.760B-$19.930B vs $19.482B Est

Boston Scientific Q2 2025 Adj. EPS $0.75 Beats $0.72 Estimate, Sales $5.061B Beat $4.892B Estimate

AMTB

ASGN

BANC

BPOP

BRKL

CADE

CBAN

CHDN

CSBR

CVBF

CVLG

EGBN

EPRT

EQNR

ESRT

First Trust Advantage Preferred Income Fund

FRME

FSBC

GLPG

GOOG

GSHD

HBNC

HCSG

ICLR

INBK

KALU

MTAL

NTST

NVEC

ORLY

OTLY

OXLC

PLXS

PTEN

QCRH

RBBN

RELL

SEIC

SIGI

Earnings Scheduled For July 23, 2025

Press Releases

Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

Boston Scientific announces results for first quarter 2025

Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints

Boston Scientific announces upcoming investor conference schedule

Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

Boston Scientific announces conference call discussing second quarter 2025 results

Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

Boston Scientific announces results for second quarter 2025

CMCT Announces 30,821-Square-Foot Lease to Boston Scientific Corporation at Penn Field, a 228,000-Square-Foot Creative Office Campus in Austin

Comments

Boston Scientific

Vendite allo scoperto

Boston Scientific (NYSE:BSX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO